Recent overviews on the moxifloxacin based novel delivery system for the treatment of bacterial keratitis

The topical route of drug administration is a primary approach to treating bacterial keratitis. The primary ocular delivery of fluoroquinolone derivative moxifloxacin is a better choice for treating bacterial infection. Recently, several new techniques have been developed to treat bacterial infections with superior efficacy, specifically moxifloxacin. This review provides a recent overview of the moxifloxacin-based newer technological system for treating bacterial keratitis through topical ocular delivery. We focused on in-situ gelling systems, different nanocarriers categorized into polymeric nanocarriers, vesicular nanocarriers, dispersed systems, ocular inserts, 3-D printing technology for pharmaceuticals, and mucoadhesive nanocarrier systems. Additionally, we have incorporated the latest research on management bacterial keratitis. Moxifloxacin based novel carrier systems that deliver moxifloxacin have led to advancements in the field of ophthalmic delivery, enhancing the drug's bioavailability and therapeutic effectiveness within the eye. 3D technology allows the creation of personalized medicine for ocular drug delivery systems. • Enlightened the influence of various nanocarrier systems through the corneal retention and permeation of drug delivery. • The positively charged mucoadhesive nanocarriers exhibited improved therapeutic efficiency and bioavailability. • The development of ocular based 3D-printing nanocarrier systems has significant interest for personalized medicine. • The system provides a low dose with less frequency of administration is required for the treatment of bacterial keratitis.